pharma · Solid Tumor, Adult · Advanced Soft-tissue Sarcoma · MNPR
Monopar Therapeutics
Monopar Therapeutics is a pharma organization headquartered in Wilmette, USA. It trades on NYSE under ticker MNPR. Primary therapeutic focus areas include Solid Tumor, Adult, Advanced Soft-tissue Sarcoma, Chemoradiothera
Wilmette, USA HQ
2015 Founded
22 Employees
Public company Type
MNPR · NYSE Ticker
Company details
- Status
- Public
- HQ
- Wilmette, USA
- Founded
- 2015
- Employees
- 22
- Programs
- 4
- Drugs
- 3
- Patents
- 3
Clonidine HCl Mucoadhesive Buccal Tablet
Phase 3 · small molecule · Chemoradiotherapy-Induced Severe Oral Mucositis
Clonidine HCl Mucoadhesive Buccal Tablet for Chemoradiotherapy-Induced Severe Oral Mucositis is a Phase 3 program (small_molecule) at Monopar Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code MNPR-301-001
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Monopar Therapeutics
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Chemoradiotherapy-Induced Severe Oral Mucositis
- Status
- terminated
- Trials
- 1